PPLPHARMA - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.2
| Stock Code | PPLPHARMA | Market Cap | 18,037 Cr. | Current Price | 136 ₹ | High / Low | 241 ₹ |
| Stock P/E | 24.4 | Book Value | 58.2 ₹ | Dividend Yield | 0.10 % | ROCE | 12.4 % |
| ROE | 9.74 % | Face Value | 10.0 ₹ | DMA 50 | 158 ₹ | DMA 200 | 180 ₹ |
| Chg in FII Hold | -0.61 % | Chg in DII Hold | 0.79 % | PAT Qtr | 151 Cr. | PAT Prev Qtr | 196 Cr. |
| RSI | 28.9 | MACD | -5.96 | Volume | 33,49,522 | Avg Vol 1Wk | 35,43,660 |
| Low price | 135 ₹ | High price | 241 ₹ | PEG Ratio | 1.10 | Debt to equity | 0.12 |
| 52w Index | 1.05 % | Qtr Profit Var | 27.4 % | EPS | 5.39 ₹ | Industry PE | 27.2 |
📊 PPLPHARMA shows moderate potential for swing trading. Fundamentals are fair with ROCE 12.4%, ROE 9.74%, and EPS of ₹5.39, while debt levels are low (0.12). Valuation is reasonable (P/E 24.4 vs industry 27.2, PEG 1.10), but technical indicators are weak: RSI at 28.9 is oversold, MACD is negative, and the stock trades below both 50 DMA and 200 DMA. The optimal entry price would be near ₹135–₹138, close to support levels. If already holding, consider exiting around ₹155–₹160, where resistance from the 50 DMA is expected.
✅ Positive
- Reasonable valuation: P/E 24.4 is slightly below industry average (27.2).
- PEG ratio at 1.10 suggests growth is aligned with valuation.
- DII holdings increased (+0.79%), showing domestic institutional support.
- Debt-to-equity ratio at 0.12 indicates low leverage risk.
⚠️ Limitation
- ROCE (12.4%) and ROE (9.74%) are modest compared to stronger peers.
- Dividend yield at 0.10% offers minimal passive income.
- Stock trading below both 50 DMA (₹158) and 200 DMA (₹180), signaling bearish trend.
- FII holdings decreased (-0.61%), showing reduced foreign investor confidence.
📉 Company Negative News
- Quarterly PAT declined from ₹196 Cr. to ₹151 Cr. (-27.4%).
- MACD negative (-5.96), indicating weak momentum.
- Stock has fallen sharply from its 52-week high of ₹241.
📈 Company Positive News
- RSI oversold (28.9), which may indicate potential for a short-term bounce.
- DII inflows provide institutional backing.
- Stable earnings base with EPS of ₹5.39.
🏭 Industry
- Industry P/E at 27.2 is slightly higher than PPLPHARMA’s, suggesting fair valuation.
- Pharmaceutical industry has strong long-term demand, driven by healthcare needs and innovation.
📝 Conclusion
PPLPHARMA is a moderately good swing trade candidate with fair valuation but weak technicals and declining profits. Entry is advisable near ₹135–₹138, with exit around ₹155–₹160 if already holding. Long-term investors should wait for improved profitability and stronger ROCE/ROE before considering significant exposure.